116 related articles for article (PubMed ID: 28837922)
1. Development of GLUT4-selective antagonists for multiple myeloma therapy.
Wei C; Bajpai R; Sharma H; Heitmeier M; Jain AD; Matulis SM; Nooka AK; Mishra RK; Hruz PW; Schiltz GE; Shanmugam M
Eur J Med Chem; 2017 Oct; 139():573-586. PubMed ID: 28837922
[TBL] [Abstract][Full Text] [Related]
2. Structure guided design and synthesis of furyl thiazolidinedione derivatives as inhibitors of GLUT 1 and GLUT 4, and evaluation of their anti-leukemic potential.
Tilekar K; Upadhyay N; Hess JD; Macias LH; Mrowka P; Aguilera RJ; Meyer-Almes FJ; Iancu CV; Choe JY; Ramaa CS
Eur J Med Chem; 2020 Sep; 202():112603. PubMed ID: 32634629
[TBL] [Abstract][Full Text] [Related]
3. The Selective SIRT3 Inhibitor 3-TYP Represses Primary Myeloma Growth by Reducing c-Myc Stability.
Zeng Y; Zhang Y; Cui Z; Mao J; Xu J; Yao R
Chem Res Toxicol; 2024 Jun; 37(6):1062-1069. PubMed ID: 38815162
[TBL] [Abstract][Full Text] [Related]
4. Evaluating the Efficacy of GLUT Inhibitors Using a Seahorse Extracellular Flux Analyzer.
Wei C; Heitmeier M; Hruz PW; Shanmugam M
Methods Mol Biol; 2018; 1713():69-75. PubMed ID: 29218518
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of Bortezomib-Induced Neuropathy Using Total Neuropathy Score (Reduced and Clinical Versions) and NCI CTCAE v4.0 in Newly Diagnosed Patients With Multiple Myeloma Receiving Bortezomib-Based Induction.
Lakshman A; Modi M; Prakash G; Malhotra P; Khadwal A; Jain S; Kumari S; Varma N; Varma S
Clin Lymphoma Myeloma Leuk; 2017 Aug; 17(8):513-519.e1. PubMed ID: 28842138
[TBL] [Abstract][Full Text] [Related]
6. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial.
Dimopoulos MA; Goldschmidt H; Niesvizky R; Joshua D; Chng WJ; Oriol A; Orlowski RZ; Ludwig H; Facon T; Hajek R; Weisel K; Hungria V; Minuk L; Feng S; Zahlten-Kumeli A; Kimball AS; Moreau P
Lancet Oncol; 2017 Oct; 18(10):1327-1337. PubMed ID: 28843768
[TBL] [Abstract][Full Text] [Related]
7. The p97 Inhibitor CB-5083 Is a Unique Disrupter of Protein Homeostasis in Models of Multiple Myeloma.
Le Moigne R; Aftab BT; Djakovic S; Dhimolea E; Valle E; Murnane M; King EM; Soriano F; Menon MK; Wu ZY; Wong ST; Lee GJ; Yao B; Wiita AP; Lam C; Rice J; Wang J; Chesi M; Bergsagel PL; Kraus M; Driessen C; Kiss von Soly S; Yakes FM; Wustrow D; Shawver L; Zhou HJ; Martin TG; Wolf JL; Mitsiades CS; Anderson DJ; Rolfe M
Mol Cancer Ther; 2017 Nov; 16(11):2375-2386. PubMed ID: 28878026
[TBL] [Abstract][Full Text] [Related]
8. Risk of Febrile Neutropenia Associated With Select Myelosuppressive Chemotherapy Regimens in a Large Community-Based Oncology Practice.
Li Y; Family L; Yang SJ; Klippel Z; Page JH; Chao C
J Natl Compr Canc Netw; 2017 Sep; 15(9):1122-1130. PubMed ID: 28874597
[No Abstract] [Full Text] [Related]
9. Synergistic antitumor effect mediated by a paclitaxel-conjugated polymeric micelle-coated oncolytic adenovirus.
Kasala D; Lee SH; Hong JW; Choi JW; Nam K; Chung YH; Kim SW; Yun CO
Biomaterials; 2017 Nov; 145():207-222. PubMed ID: 28869866
[TBL] [Abstract][Full Text] [Related]
10. Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM.
Moreau P; Chanan-Khan A; Roberts AW; Agarwal AB; Facon T; Kumar S; Touzeau C; Punnoose EA; Cordero J; Munasinghe W; Jia J; Salem AH; Freise KJ; Leverson JD; Enschede SH; Ross JA; Maciag PC; Verdugo M; Harrison SJ
Blood; 2017 Nov; 130(22):2392-2400. PubMed ID: 28847998
[TBL] [Abstract][Full Text] [Related]
11. Beyond first-line non-anthracycline-based chemotherapy for extranodal NK/T-cell lymphoma: clinical outcome and current perspectives on salvage therapy for patients after first relapse and progression of disease.
Lim SH; Hong JY; Lim ST; Hong H; Arnoud J; Zhao W; Yoon DH; Tang T; Cho J; Park S; Ko YH; Kim SJ; Suh C; Lin T; Kim WS
Ann Oncol; 2017 Sep; 28(9):2199-2205. PubMed ID: 28911074
[TBL] [Abstract][Full Text] [Related]
12. The mTOR inhibitor everolimus in combination with azacitidine in patients with relapsed/refractory acute myeloid leukemia: a phase Ib/II study.
Tan P; Tiong IS; Fleming S; Pomilio G; Cummings N; Droogleever M; McManus J; Schwarer A; Catalano J; Patil S; Avery S; Spencer A; Wei A
Oncotarget; 2017 Aug; 8(32):52269-52280. PubMed ID: 28881728
[TBL] [Abstract][Full Text] [Related]
13. Impact of neoadjuvant chemotherapy and postoperative adjuvant chemotherapy cycles on survival of patients with advanced-stage ovarian cancer.
Chung YS; Kim YJ; Lee I; Lee JY; Nam EJ; Kim S; Kim SW; Kim YT
PLoS One; 2017; 12(9):e0183754. PubMed ID: 28873393
[TBL] [Abstract][Full Text] [Related]
14. Doxorubicin-loaded oligonucleotide conjugated gold nanoparticles: A promising in vivo drug delivery system for colorectal cancer therapy.
Lee CS; Kim H; Yu J; Yu SH; Ban S; Oh S; Jeong D; Im J; Baek MJ; Kim TH
Eur J Med Chem; 2017 Dec; 142():416-423. PubMed ID: 28870452
[TBL] [Abstract][Full Text] [Related]
15. Gefitinib-loaded DSPE-PEG2000 nanomicelles with CD133 aptamers target lung cancer stem cells.
Huang X; Huang J; Leng D; Yang S; Yao Q; Sun J; Hu J
World J Surg Oncol; 2017 Aug; 15(1):167. PubMed ID: 28854941
[TBL] [Abstract][Full Text] [Related]
16. Autologous Fat Grafting as a Novel Antiestrogen Vehicle for the Treatment of Breast Cancer.
Thomas S; Chen S; Sbitany H; Kwon E; Piper M; Park J; Terranova Barberio M; Pawlowska N; Munster PN
Plast Reconstr Surg; 2017 Sep; 140(3):537-544. PubMed ID: 28841614
[TBL] [Abstract][Full Text] [Related]
17. Insulin-promoted mobilization of GLUT4 from a perinuclear storage site requires RAB10.
Brumfield A; Chaudhary N; Molle D; Wen J; Graumann J; McGraw TE
Mol Biol Cell; 2021 Jan; 32(1):57-73. PubMed ID: 33175605
[TBL] [Abstract][Full Text] [Related]
18. Targeting metabolism to enhance immunotherapy within tumor microenvironment.
Liang XH; Chen XY; Yan Y; Cheng AY; Lin JY; Jiang YX; Chen HZ; Jin JM; Luan X
Acta Pharmacol Sin; 2024 May; ():. PubMed ID: 38811773
[TBL] [Abstract][Full Text] [Related]
19. Metabolic features of myeloma cells in the context of bone microenvironment: Implication for the pathophysiology and clinic of myeloma bone disease.
Raimondi V; Toscani D; Marchica V; Burroughs-Garcia J; Storti P; Giuliani N
Front Oncol; 2022; 12():1015402. PubMed ID: 36313705
[TBL] [Abstract][Full Text] [Related]
20. Targeting Glucose Metabolism Enzymes in Cancer Treatment: Current and Emerging Strategies.
Zhang Y; Li Q; Huang Z; Li B; Nice EC; Huang C; Wei L; Zou B
Cancers (Basel); 2022 Sep; 14(19):. PubMed ID: 36230492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
